ライフサイエンスコーパス: luteinizing hormone-releasing hormone

1 g orexin, melanin-concentrating hormone, and luteinizing hormone-releasing hormone.

2 steroid ablation using leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), i

3 Luteinizing hormone-releasing hormone agonist (LHRHa; le

4 AST, which was defined as 6 months of both a luteinizing hormone-releasing hormone agonist and an ant

5 ts receiving combined androgen blockade with luteinizing hormone-releasing hormone agonist and bicalu

6 les, followed by total androgen suppression (luteinizing hormone-releasing hormone agonist plus bical

7 tients were randomized soon after initiating luteinizing hormone-releasing hormone agonist with antia

8 n deprivation (AD) to cixutumumab added to a luteinizing hormone-releasing hormone agonist with bical

9 S; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primar

10 Patients were randomly assigned 2:1 to a luteinizing hormone-releasing hormone agonist, bicalutam

11 Bilateral orchiectomy or luteinizing hormone releasing hormone agonists are the r

12 Bilateral orchiectomy or luteinizing hormone-releasing hormone agonists are recom

13 ; and three, when chemical suppression using luteinizing hormone-releasing hormone agonists is the ch

14 For luteinizing hormone-releasing hormone, all but two expec

15 ombesin (AN-215), somatostatin (AN-238), and luteinizing hormone-releasing hormone (AN-207) consisted

16 Luteinizing hormone releasing hormone analog (LHRHa, des

17 state cancer were performed before and after luteinizing hormone-releasing hormone analog treatment.

18 of 5 ng per milliliter or higher received a luteinizing hormone-releasing hormone analogue and an an

19 Whether the administration of luteinizing hormone-releasing hormone analogues (LHRHa)

20 d cutaneous depolarization were blocked by a luteinizing hormone-releasing hormone antagonist.

21 in, corticotropin-releasing factor, galanin, luteinizing hormone-releasing hormone, enkephalin, subst

22 Luteinizing hormone-releasing hormone immunoreactivity w

23 rporation into targeted cytotoxic analogs of luteinizing hormone-releasing hormone intended for cance

24 odoxorubicin (AN-201) conjugated to [D-Lys6] luteinizing hormone-releasing hormone (LH-RH) (AN-207),

25 ound that the t(1/2) of AN-152, an analog of luteinizing hormone-releasing hormone (LH-RH) containing

26 Treatment with antagonists of luteinizing hormone-releasing hormone (LH-RH) leads to d

27 bit nitric oxidergic (NOergic) activation of luteinizing hormone-releasing hormone (LH-RH) release fr

28 eloped a targeted cytotoxic analog AN-207 of luteinizing hormone-releasing hormone (LH-RH), consistin

29 152, a conjugate of doxorubicin and [D-Lys6]-luteinizing hormone-releasing hormone (LH-RH), is more p

30 Antagonists of luteinizing hormone-releasing hormone (LH-RH), unlike th

31 d into agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH).

32 synthesis, is involved in the suppression of luteinizing hormone releasing hormone (LHRH) before pube

33 favorable for the release of a neuropeptide, luteinizing hormone releasing hormone (LHRH) from these

34 Luteinizing hormone releasing hormone (LHRH) gene transc

35 n of prostaglandin E2, which then stimulates luteinizing hormone releasing hormone (LHRH) neurons to

36 dy single-chain variable fragment (scFv) and luteinizing hormone releasing hormone (LHRH) peptide, re

37 Exogenous luteinizing hormone releasing hormone (LHRH) potentiated

38 Cytotoxic analogue of luteinizing hormone releasing hormone (LHRH), AN-207, bi

39 Irradiation of luteinizing hormone releasing hormone (LHRH), growth hor

40 n releasing hormone-1 [GnRH-1, also known as luteinizing hormone releasing hormone (LHRH)] neurons ca

41 Previously, we have shown that two types of luteinizing hormone-releasing hormone (LHRH) -like neuro

42 The effects of depot formulations of the luteinizing hormone-releasing hormone (LHRH) agonist Dec

43 Treatment with a luteinizing hormone-releasing hormone (LHRH) agonist inc

44 orticotropic hormone (ACTH) and hypothalamic luteinizing hormone-releasing hormone (LHRH) agonist, [D

45 Ovarian suppression with luteinizing hormone-releasing hormone (LHRH) agonists is

46 the recent developments on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist

47 tance and (5) a modified synthetic analog of luteinizing hormone-releasing hormone (LHRH) as a target

48 Neurons differentiating into the luteinizing hormone-releasing hormone (LHRH) neuroendocr

49 ergic expression coincides with migration of luteinizing hormone-releasing hormone (LHRH) neurons fro

50 id (GABAergic) synaptic input onto embryonic luteinizing hormone-releasing hormone (LHRH) neurons mai

51 Luteinizing hormone-releasing hormone (LHRH) neurons mig

52 Luteinizing hormone-releasing hormone (LHRH) neurons mig

53 Luteinizing hormone-releasing hormone (LHRH) neurons ori

54 Luteinizing hormone-releasing hormone (LHRH) neurosecret

55 uropeptide Y (NPY) potentiates the effect of luteinizing hormone-releasing hormone (LHRH) on luteiniz

56 Functionalized with luteinizing hormone-releasing hormone (LHRH) peptide via

57 To investigate the possibility that a second luteinizing hormone-releasing hormone (LHRH) population

58 Importantly, SSA induced by luteinizing hormone-releasing hormone (LHRH) receptor an

59 To understand the mechanism of pulsatile luteinizing hormone-releasing hormone (LHRH) release, we

60 low doses (5-30 nM) induced large amounts of luteinizing hormone-releasing hormone (LHRH) release, wh

61 implicated in the neuroendocrine control of luteinizing hormone-releasing hormone (LHRH) secretion a

62 estigate the mechanism by which Mn2+ induces luteinizing hormone-releasing hormone (LHRH) secretion f

63 s by which the neuroendocrine brain controls luteinizing hormone-releasing hormone (LHRH) secretion.

64 Luteinizing hormone-releasing hormone (LHRH) was used as

65 large doses of Cetrorelix, an antagonist of luteinizing hormone-releasing hormone (LHRH), reduces le

66 naling pathway that prompts the secretion of luteinizing hormone-releasing hormone (LHRH), the neurop

67 osecretory neurons to stimulate secretion of luteinizing hormone-releasing hormone (LHRH), the neurop

68 ure activation of those neurons that produce luteinizing hormone-releasing hormone (LHRH), the neurop

69 t of norepinephrine (NE) on the secretion of luteinizing hormone-releasing hormone (LHRH), the neurop

70 ne (LH) surge that is prompted by a surge in luteinizing hormone-releasing hormone (LHRH).

71 othalamic neurons secreting the neuropeptide luteinizing hormone-releasing hormone (LHRH).

72 ng afferent pathways to neurons synthesizing luteinizing hormone-releasing hormone (LHRH, also known

73 itive tumors also received letrozole (plus a luteinizing hormone-releasing hormone [LHRH] agonist if

74 diation plus immediate androgen suppression (luteinizing hormone-releasing hormone [LHRH] agonist), w

75 that FSHRF might be an analogue of mammalian luteinizing hormone-releasing hormone (m-LHRH) and evalu

76 coexpressed in neurons containing mammalian luteinizing hormone-releasing hormone (m-LHRH).

77 k suggests that cytotoxic peptide analogs of luteinizing hormone-releasing hormone, somatostatin, and

78 s monotherapy or with adjuvant castration or luteinizing hormone-releasing hormone superagonists to b